[Liver toxicity of combined rifampicin-isoniazid-ethambutol medication (author's transl)].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury; D002779:Cholestasis; D004796:Clinical Enzyme Tests; D004359:Drug Therapy, Combination / Q000009:adverse effects; D004977:Ethambutol / Q000627:therapeutic use; D005234:Fatty Liver / Q000150:complications; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008107:Liver Diseases / Q000175:diagnosis / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D012293:Rifampin / Q000627:therapeutic use / Q000633:toxicity*; D013448:Sulfobromophthalein; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D013448:Sulfobromophthalein; D004977:Ethambutol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin; D007538:Isoniazid; D012293:Rifampin
Lebertoxizität einer Rifampicin-Kombinationstherapie